-
Innovation Ranking
NewInnovation Ranking – Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc (Corvus Pharma) is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of immuno-oncology therapies that are used for treating cancer. Corvus Pharma's product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in phase I clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine produced by the tumor cells. Corvus Pharma’s product pipeline...
-
Sector Analysis
NewHungary Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Hungary Defense Market Report Overview In 2024, Hungary's defense budget is worth $4.6 billion. The country’s defense budget will grow at a CAGR of more than 6% during 2025-2029. The largest component of Hungary’s defense expenditure every year is acquisition. This is the result of the ongoing ZrÃnyi Modernization Program to update Hungary’s aging military equipment, much of which is still a holdover from the Soviet era. Hungary Defense Market Outlook, 2024-2029 ($ Billion) Buy the Full Report for More...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Colorectal Cancer Drug Details: ATX-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soquelitinib in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soquelitinib in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Soquelitinib (CPI-818)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soquelitinib in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in T-Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soquelitinib in T-Cell Lymphomas Drug Details: Soquelitinib (CPI-818) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soquelitinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soquelitinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ciforadenant in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ciforadenant in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ciforadenant in Relapsed Multiple Myeloma Drug Details: Ciforadenant is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mupadolimab in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mupadolimab in Oropharyngeal Cancer Drug Details: Mupadolimab (CPI-006) is under development for...